Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of SLC25A26 in preparation of medicine for inhibiting cardiac hypertrophy

A 1.SLC25A26, myocardial hypertrophy technology, applied in the field of biomedicine, can solve problems such as ambiguity

Active Publication Date: 2021-11-02
中国医学科学院阜外医院深圳医院
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Intracellular SAM utilizes the SAM sensor upstream of mTORC1 (SAM sensor upstream of mTORC1, SAMTOR or BMT2) and is closely related to the mTOR signaling pathway, but whether this regulatory process is involved in the process of cardiac hypertrophy is not yet clear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of SLC25A26 in preparation of medicine for inhibiting cardiac hypertrophy
  • Application of SLC25A26 in preparation of medicine for inhibiting cardiac hypertrophy
  • Application of SLC25A26 in preparation of medicine for inhibiting cardiac hypertrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0040] The experimental method in the present embodiment of the present invention is as follows:

[0041] 1. Animal feeding

[0042] All animal experimental procedures were reviewed and approved by the Animal Care and Use Committee (IACUC) of Renmin Hospital of Wuhan University, and implemented in accordance with the Guidelines for the Care and Use of Laboratory Animals (8th Edition) published by the National Institutes of Health (USA). . All mice were reared in an SPF environment, room temperature 24±3°C, humidity 55±5%, 12-hour light / 12-hour dark cycle, and fed normal diet. Nine-week-old male mice of C57BL / 6 were used in this study. C57BL / 6 7-week-old male mice were randomly divided into two groups, and equal amounts of AAV9-GFP and AAV9-Slc25a26 viruses were injected through the tail vein.

[0043] 2. Isolation and culture of primary rat cardiomyocytes (NRVM)

[0044] The chest skin of SD rat neonatal suckling mice (within 3 days after birth) was disinfected with 75% et...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to application of SAM transporter solute carrier family 25 member 26 (SLC25A26) in preparation of a medicine for inhibiting myocardial hypertrophy. The application finds that SLC25A26 is dynamically adjusted in the cardiac hypertrophy process. The SLC25A26 is used as an anti-myocardial hypertrophy factor, and the protein synthesis rate is adjusted by controlling the SAM level in cytoplasm and SAMTOR / mTOR signal transduction. According to the present invention, with the overexpression of the SLC25A26 mediated by the AAV9 in the heart of the mouse, the pathological process of the cardiac hypertrophy induced by the TAC can be significantly improved; the application illustrates the effect of protein translation regulation in the cardiac hypertrophy process, and provides a new thought for preventing and treating heart failure through targeted regulation of protein synthesis.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of SLC25A26 in the preparation of drugs for inhibiting cardiac hypertrophy. Background technique [0002] In the case of increased cardiac afterload, in order to adapt to changes in hemodynamics, the heart develops compensatory myocardial hypertrophy. Before heart failure, cardiac hypertrophy is characterized by increased cardiomyocyte volume and increased protein synthesis. Among them, metabolic changes can micro-regulate protein translation activity. In the process of cardiac hypertrophy, how cells maintain protein homeostasis by coordinating metabolic state remains to be further studied. [0003] Major regulation of translation occurs in the nucleolus, including transcription of ribosomal DNA and assembly of ribosomal subunits. Cardiac hypertrophy was one of the first diseases found to be associated with ribosomal DNA transcription disorders....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K31/436A61P9/00A61P9/04
CPCA61K45/00A61K31/436A61P9/00A61P9/04
Inventor 王志华郭宁宁吕舰
Owner 中国医学科学院阜外医院深圳医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com